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 THROMBOTIC AND HEMORRHAGIC COMPLICATIONS IN IDIOPATHIC ERYTHROCYTOSIS 
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To the Editor 
 
The diagnosis of Idiopathic erythrocytosis (IE) is ruled out when all the known causes of 
erythrocytosis are excluded after a complete and accurate diagnostic process.   
The estimated prevalence of IE is 1.1 cases per 1,000 persons, for secondary acquired 
erythrocytosis (SAE), mediated by altere\d production of erythropoietin, is 2.2 per 1,000 persons 
[1] and for polycythemia vera (PV), a myeloproliferative neoplasm characterized by a consistent 
risk of hemorrhagic and thrombotic complications, is 0.3 per 1,000 persons.  Therefore, the 
prevalence of IE is four times higher than PV and half than SAE in general population [2]. 
In spite of its relative frequency, few papers have focused on IE and information about thrombotic 
and haemorrhagic risk in this setting are lacking. 
We report clinical features of a large cohort of patients with IE compared to a cohort of patients 
with PV, focusing on the thrombotic and hemorrhagic risk. 
Between 1980 and 2015, we studied and followed 145 patients with IE in two Centers of Veneto 
Region,Italy, expert in the field of erythrocytosis. In these patients, all known causes of familial 
and SAE were excluded and JAK2V617F or JAK2 exon 12 mutations were not found. As controls, 
we used 145 patients with PV, strictly diagnosed in agreement with WHO criteria, studied in the 
same period and matched for Ht values.  
We collected in all IE and PV patients disease-relevant parameters, including blood count at 
diagnosis, thrombosis, hemorrhages, progression into overt myelofibrosis, leukemic 
transformation, and death. All patients were treated with phlebotomies, to maintain hematocrit 
(Ht) below 45% and when appropriate, they received low dose aspirin. Eighty (54.8 %) PV patients 
were treated with hydroxyurea for high platelet count or symptomatic splenomegaly or after 
vascular complications.   
The statistical tests adopted were Mann-Whitney U-test, χ2 test or Fisher’s exact test as 
appropriate, Kaplan-Meier method for survivals, Log Rank test, Cox proportional hazard regression 
model. 
Main clinical and laboratory data of our patients are summarized in table 1. 
Twenty-one (14.5%) patients with IE and 39 (26.9%) with PV (p=0.01) experienced at least one 
thrombotic event. Five IE (3.4%) and 12 PV (8.3%) had a thrombotic event (p=NS) at presentation 
of erythrocytosis. The thrombotic events were 3 arterial and 2 venous in IE  and 3 arterial and 9 
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venous in PV. During follow-up, 16 patients with IE (11%) and 27 with PV (18.6%) experienced 
thrombotic complications (p=0.047). Venous events were 2 (2 deep vein thrombosis -DVT) in IE 
and 15 (8 DVT, 3 pulmonary embolism, 4 splanchnic vein thrombosis) in PV (p=0,002). Arterial 
complications occurred in 13 IE (7 myocardial infarction -MI, 4 stroke, 2 transitory ischemic attack 
-TIA) and in 12 PV (5 MI, 1 stroke, 5 TIA and 1 peripheral arterial thrombosis) with no significant 
difference. Thrombosis free survival was significantly shorter in PV patients (p=0.005) (Fig 1). The 
thrombotic incidence rate was 3% patients/year in PV and 1.5% patients/year in IE (IRR = 2). IE 
displays a significant lower risk of developing thrombosis than PV also in age and sex adjusted 
multivariable analysis (HR 0.471, 95% CI 0.242 – 0.915; p=0.026). 
During follow-up, 7 (4.8%) patients with IE (1 gastro-intestinal and 6 minor hemorrhage) and 22 
(15.2%) with PV (6 major and 16 minor hemorrhage) suffered for bleedings with a significant 
difference between the two cohorts (p=0.005). In particular, 4 IE (5.4%) bleed compared to 19 PV 
(16%) (p=0.02) during the use of aspirin. Also Hemorrhagic Free survival was dramatically different 
(p=0.002)(Fig 2). The hemorrhagic incidence rate was 0.57% patients/year in IE and 2.01% 
patients/year in PV (IRR=0.28). Low dose aspirin was administered in 81.4% of PV and in 50.3% of 
IE (p=0.001).  Cox multivariable analysis, including age, sex, platelet count at diagnosis and low-
dose aspirin therapy, confirms the significant lower risk of bleedings in IE compared to PV (HR 
0.27, 95% CI 0.091 – 0.792; p = 0.017). 
Being few papers focusing on IE [2,3,4], we ignore the real outcome of this disease. We know that 
IE is an indolent form and it does not evolve into myelofibrosis or acute leukemia, unlike PV. IE is 
frequent in males suggesting that hormonal activity could play a significant role [3]: increased red 
blood cell mass is the most common adverse event associated with testosterone therapy in clinical 
practice and experimental data suggest that testosterone stimulates erythropoiesis by stimulating 
EPO and increasing iron utilization for erythropoiesis [5].  
In the present cohort, IE patients have a lower risk of thrombosis (1.5/100 patients/year) than PV 
(3/100 patients/year) possibly because in PV platelets and WBC are frequently increased while 
they are normal in IE [3]. A significantly poorer thrombosis free survival of PV comparing IE 
confirms this observation. Interestingly, only 2 out of our IE patients suffered for venous 
thrombosis during follow-up with a lower incidence compared to PV patients while arterial events 
are similarly distributed among PV and IE. Recent data [6] suggest that red blood cells 
independently promote arterial thrombosis increasing the rate of platelet deposition and 
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thrombus growth: this may explain the occurrence of arterial thrombosis in IE and not only in PV 
patients. 
A bleeding incidence rate in IE about 4 times lower than in PV (2.9/100 patients/year), not 
increased by the use of low-dose aspirin, has been observed in the present cohort. In agreement, 
the haemorrhage free survival is longer in IE patients compared to PV.  
In conclusion, IE has a lower thrombotic and hemorrhagic risk than PV in spite of a stringent 
program of phlebotomies and a frequent use of low dose aspirin. Prospective, randomized study 
are needed to reinforce our results.  
 
 
Acknowledgement: the study was supported in part by the University of Padua DOR funding. 
  
Page 4 of 6
John Wiley & Sons
American Journal of Hematology
This article is protected by copyright. All rights reserved.
References 
1) Ruggeri M, Tosetto, A., Frezzato M, Rodeghiero F. The rate of progression to polycythemia vera 
or essential thrombocythemia in patients with erythrocytosis or thrombocytosis. Ann Intern Med 
2003;139,470–475.  
2) Finazzi G, Gregg X T, Barbui T, Prchal J T. Idiopathic erythrocytosis and other non-clonal 
polycythemias. Best Pract Res Clin Haematol 2006;19:471–482.  
3) Randi ML, Bertozzi, I, Cosi E, Santarossa C, Peroni E, Fabris F. Idiopathic erythrocytosis: a study 
of a large cohort with a long follow-up. Ann Hematol 2016;95: 233–237.  
4) McMullin MF. Diagnosis and management of congenital and idiopathic erythrocytosis. Ther Adv 
Hematol 2012;3, 391–398 
5) Bachman E, Travison TG, Basaria S, et al. Testosterone induces erythrocytosis via increased 
erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. 
J Gerontol A Biol Sci Med Sci 2014 June;69(6):725–735 
6) Walton BL, Lehmann M, Skorczewski T, et al: Elevated Hematocrit enhances platelet 
accumulation following vascular injury. Blood March 1, 2017; DOI 10.1182/blood-2016-10-746479 
 
 
 
Page 5 of 6
John Wiley & Sons
American Journal of Hematology
This article is protected by copyright. All rights reserved.
Table 1: Main clinical and laboratory data of our patients with erythrocytosis 
IE = Idiopathic Erythrocytosis, PV= Polycythemia Vera 
 
 IE PV P 
Patients, n 145 145 - 
Males, n (%) 127 (87.6) 83 (57.2) <0.001 
Median age at diagnosis, years (5
th
 – 95
th
 
Percentile) 
56.5 (21.2 – 
75.8) 
61.7 (30.3 – 
81.9) 
0.006 
Median follow up, years (5
th
 – 95
th
 Percentile) 6.6 (0.3 – 23.2) 7.4 (0.3 – 22.1) n.s. 
Median WBC, x 10
9
/L (5
th
 – 95
th
 Percentile) 7.2 (5 – 11.9) 8.7 (5.7 – 17.3) <0.001 
Median Hb, g/L (5
th
 – 95
th
 Percentile) 179 (164 – 195) 175 (149 – 213) 0.03 
Median Ht, % (5
th
 – 95
th
 Percentile) 52.8 (48.3 – 
57.8) 
53.1 (46.2 – 
66.2) 
n.s. 
Median plts count, x 10
9
/L (5
th
 – 95
th
 
Percentile) 
217 (132 – 320) 485 (209 – 882) <0.001 
Patients with at least a thrombosis, n (%) 21 (14.5) 39 (26.9) 0.01 
Patients with at least a hemorrhage, n (%) 7 (4.8) 22 (15.2%) 0.005 
Patients treated with low-dose aspirin, n (%) 73 (50.3) 118 (81.4) 0.001 
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